Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 3

3(37.5%)

Phase 2

1(12.5%)

8Total

Phase 1(4)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06010953Phase 1Completed

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Role: lead

NCT06136507Phase 3Not Yet Recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Role: lead

NCT06142552Phase 3Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Role: lead

NCT04864743Phase 1Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Role: lead

NCT04845399Phase 3Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Role: collaborator

NCT05251090Phase 1Completed

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Role: lead

NCT05651061Phase 1Completed

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Role: lead

NCT05265286Phase 2Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Role: lead

All 8 trials loaded